Sanofi India share price gained up to 6% in morning trades on Friday post Q4 results announced by the company after the ...

The Phase I trial will recruit approximately 98 healthy volunteers and adults living with atopic dermatitis at a single site ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

For GSK CEO Emma Walmsley, there was good news and bad news in the company’s annual report. | For GSK CEO Emma Walmsley, ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

An FDA vaccine advisory committee meeting to discuss next season’s flu vaccine has been canceled, potentially delaying the ...

The company's molecular research and drug-development platform taps what it calls nature's wisdom to drive the discovery of ...

Novavax is starting to look like a vaccine development company again. And 2025 stands to be a big year for the local biotech.

Novavax (NVAX) reported a large fourth quarter sales decline Thursday — and said it no longer wants to be known simply as a ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...